BD OptiBuildTM BV421 Mouse Anti-Human Siglec-8

Description

Flow cytometric analysis of Siglec-8 expression on peripheral blood granulocytes. Whole blood was stained with PE Mouse Anti-Human CD193 Cat. No. 561746 or 558165 with no additional stain to show the degree of eosinophil autofluorescence; Left Plot or costained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; Middle Plot or BD OptiBuild BV421 Mouse Anti-Human Siglec-8 Cat. No. 747875; Right Plot at 0.25 mug/test. The stained cells were then treated with 1 BD Pharm Lyse lysing solution Cat. No. 555899 to remove erythrocytes. The pseudocolor dot plots showing Siglec-8 or Ig isotype control staining or autofluorescence versus CD193 were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Flow cytometric analysis of Siglec-8 expression on peripheral blood granulocytes. Whole blood was stained with PE Mouse Anti-Human CD193 Cat. No. 561746 or 558165 with no additional stain to show the degree of eosinophil autofluorescence; Left Plot or costained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; Middle Plot or BD OptiBuild BV421 Mouse Anti-Human Siglec-8 Cat. No. 747875; Right Plot at 0.25 mug/test. The stained cells were then treated with 1 BD Pharm Lyse lysing solution Cat. No. 555899 to remove erythrocytes. The pseudocolor dot plots showing Siglec-8 or Ig isotype control staining or autofluorescence versus CD193 were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Flow cytometric analysis of Siglec-8 expression on peripheral blood granulocytes. Whole blood was stained with PE Mouse Anti-Human CD193 Cat. No. 561746 or 558165 with no additional stain to show the degree of eosinophil autofluorescence; Left Plot or costained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; Middle Plot or BD OptiBuild BV421 Mouse Anti-Human Siglec-8 Cat. No. 747875; Right Plot at 0.25 mug/test. The stained cells were then treated with 1 BD Pharm Lyse lysing solution Cat. No. 555899 to remove erythrocytes. The pseudocolor dot plots showing Siglec-8 or Ig isotype control staining or autofluorescence versus CD193 were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Show More Flow cytometric analysis of Siglec-8 expression on peripheral blood granulocytes. Whole blood was stained with PE Mouse Anti-Human CD193 Cat. No. 561746 or 558165 with no additional stain to show the degree of eosinophil autofluorescence; Left Plot or costained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; Middle Plot or BD OptiBuild BV421 Mouse Anti-Human Siglec-8 Cat. No. 747875; Right Plot at 0.25 mug/test. The stained cells were then treated with 1 BD Pharm Lyse lysing solution Cat. No. 555899 to remove erythrocytes. The pseudocolor dot plots showing Siglec-8 or Ig isotype control staining or autofluorescence versus CD193 were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Show More Flow cytometric analysis of Siglec-8 expression on peripheral blood granulocytes. Whole blood was stained with PE Mouse Anti-Human CD193 Cat. No. 561746 or 558165 with no additional stain to show the degree of eosinophil autofluorescence; Left Plot or costained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; Middle Plot or BD OptiBuild BV421 Mouse Anti-Human Siglec-8 Cat. No. 747875; Right Plot at 0.25 mug/test. The stained cells were then treated with 1 BD Pharm Lyse lysing solution Cat. No. 555899 to remove erythrocytes. The pseudocolor dot plots showing Siglec-8 or Ig isotype control staining or autofluorescence versus CD193 were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Flow cytometric analysis of Siglec-8 expression on peripheral blood granulocytes. Whole blood was stained with PE Mouse Anti-Human CD193 Cat. No. 561746 or 558165 with no additional stain to show the degree of eosinophil autofluorescence; Left Plot or costained with either BD Horizon BV421 Mouse IgG1, kappa Isotype Control Cat. No. 562438; Middle Plot or BD OptiBuild BV421 Mouse Anti-Human Siglec-8 Cat. No. 747875; Right Plot at 0.25 mug/test. The stained cells were then treated with 1 BD Pharm Lyse lysing solution Cat. No. 555899 to remove erythrocytes. The pseudocolor dot plots showing Siglec-8 or Ig isotype control staining or autofluorescence versus CD193 were derived from gated events with the forward and side light-scatter characteristics of viable granulocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot.